MACNICA,-INC.
7.11.2016 11:02:05 CET | Business Wire | Press release
Macnica, Inc., a global leader in distributing semiconductors, electronic components, and network equipment, with its headquarter located in 1-6-3 Shin-Yokohama, Kohoku-ku, Yokohama, Japan (“Macnica”), today expanded its Mpression IP portfolio releasing SLVS-EC interface IP core for ALTERA FPGA compliant with SLVS-EC interface technology newly incorporated into Sony CMOS Image Sensor. Users can quickly develop and introduce their products early into market with SLVS-EC technology.
Macnica is a global, technology oriented distributor particularly focusing on demand creation. Macnica not only offers outstanding technical support for its product lines but also provides its original products and services under its “Mpression” brand for satisfying customer needs and solving issues.
Sony CMOS Image Sensor with SLVS-EC interface capable of high speed data
transfer will be introduced into CMOS Image Sensor market to satisfy
needs for trending higher resolution and higher framerate.
Mpression
SLVS-EC Rx IP Macnica has developed can support and contribute users who
develop advanced products supporting SLVS-EC interface.
Macnica has paid attention to SLVS-EC interface in the early days and
realized a world first solution to receive high speed image data
transmitted over SLVS-EC interface on ALTERA FPGA.
Now, the IP
enables to connect Sony high resolution and high framerate CMOS Image
Sensor to FPGA easily. It is ideal for a various applications like the
products with CMOS image sensor and FPGA to receive the image data.
Macnica is licensing the IP worldwide through its subsidiaries or
partners. ATD Electronique, an affiliate of Macnica sells and supports
it in Europe.
Macnica will exhibit demonstration of SLVS-EC Rx IP
at the booth of ATD Electronique in VISION SHOW held in Stuttgart,
Germany from November 8 to 10. Please don’t forget to visit us.
|
VISION SHOW Information |
||
| Name of Exhibition |
VISION
Leading world trade fair for machine vision |
|
| Schedule | 08 - 10 November 2016 | |
| Place | Messe Stuttgart | |
| Booth No. of ATD Electronique | Hall 1, E82 | |
* All company names and product names mentioned herein are trademarks or registered trademarks of their respective owners.
About Macnica:
Macnica has been established since 1972 as a semiconductor distribution company headquartered in Yokohama, Japan servicing customers in Japan, the Americas and Asia through its 75 sales offices around the world. Total number of employees is over 2,000 worldwide and total revenue for fiscal 2015 was approximately US$4B. Macnica is famous for having an excellent engineering team of more than 800 application engineers with strong focus on providing technical support for its customers. Macnica is continuing to improve its presence globally by having successful partners in strategic areas in the electronics market. Macnica Inc. and ATD Electronique have entered into an agreement for Macnica to acquire 49% of ATD’s outstanding shares on July 22nd, 2016.
About ATD Electronique:
ATD Electronique, who was founded in 1990 represents and distributes innovative electronic component brands and offers engineering services for machine vision and imaging applications through its offices in France and Germany and its representatives in Italy and Spain. Its product portfolio includes image sensors, controller & interface ICs, ISPs as well as development tools and design services enabling fast and efficient realization of new high performance camera systems for markets such as automotive, medical, security and machine vision.
About Mpression:
Mpression represents an integration and collection of all original
technology solutions of Macnica group such as software, platforms,
evaluation boards, and others which has been developed, provided and
supported in each country by each Macnica group companies.
Macnica
provides its advanced and ready-to-use system level solutions to
customers based on the accumulated know-hows by the very experienced
engineers from worldwide group companies, and thus leads to maximizing
the value of products as well as shortening customer's development time.
Macnica
is going to propose and support the IP offering one-stop services
through its group companies in all regions from country to country in
Europe, USA, China, and Asia.
Please visit our web-site (http://m-pression.com/
)
for a full detail of Mpression.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005041/en/
Contact:
Macnica, Inc.
Hajime Nakamura, 81-45-470-9838
Sales Planning,
Advanced Technology
AtdSpl@macnica.co.jp
FAX:
81-45-470-9857
Macnica Bldg No.2, 1-5-5 Shin-Yokohama, Kouhoku-ku,
Yokohama, 222-8563 JAPAN
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
